Search
Research
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocolPneumonia is the leading cause of childhood morbidity and mortality globally.
Research
Potential impact of a maternal vaccine for RSV: A mathematical modelling studyRespiratory syncytial virus is a major cause of respiratory morbidity and one of the main causes of hospitalisation in young children.
Research
Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus SheddingWe assessed replication and excretion of the live attenuated CYD-TDV into biological fluids following vaccination in dengue-naive adults in Australia.
Research
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2015: the Influenza Complications Alert NetworkThis report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2015 influenza season
Research
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexityThere has been a coordinated effort from academic institutions and the PI to identify biomarkers that can predict immune checkpoint blockade response in cancer.
Research
Clinical Predictors of Influenza in Young Children: The Limitations of “Influenza-Like Illness”This study aims to identify clinical predictors of influenza infection in children ≤5 years old from which age-specific ILI definitions are then constructed.
Research
Pandemic clinical case definitions are non-specificDuring the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.
Research
A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of AgeWe assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age.
Research
Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapyIn adults, the unpredictability of voriconazole pharmacokinetics, particularly in those patients receiving chemotherapy, is well recognised. A paucity of...